According to a statement by the DZIF, a potential vaccine against SARS-CoV-2 is to be tested in initial clinical trials on humans before the end of this year.
More and more people are wondering when the first vaccination against the new coronavirus will be available.
Researchers around the world are working on vaccines.
As the German Centre for Infection Research (DZIF) has now reported, a vaccine is currently being produced for the clinical test phase.
It is repeatedly pointed out that the danger posed by the coronavirus SARS-CoV-2 will not be averted until a vaccine against the novel pathogen is available.
Researchers from Germany now report that clinical tests for a vaccine against the coronavirus can be started in just a few months.
SARS-CoV-2 vaccine: clinical test phase can begin soon
“The blueprint for the vaccine is ready.
Now the vaccine still has to be produced for the clinical tests,” explains Prof.
Stephan Becker, head of the Institute of Virology at the University of Marburg and coordinator of the “Emerging Infectious Diseases” division at the DZIF.
“We now have everything together financially and logistically in order to soon start a phase I clinical trial,” adds the expert.
Construction plan for the vaccine is already ready
According to the information provided, this phase involves testing for tolerance and stimulation of immune responses.
In Marburg, the immune monitoring, i.e. the characterisation of the antibody response to the vaccine, will take place.
The vaccine is currently being produced for clinical phase I.
According to the announcement, production is expected to be completed in three months so that clinical trials can start in September.
The vaccine candidate for Phase I clinical trials has been developed under the direction of Prof. Dr. Dr. Dr. Michael Kroes.
Gerd Sutter of the Ludwig-Maximilians-University (LMU) Munich.
Although the development is much faster than previous procedures, no vaccine will be available this year.
“The development of a vaccine is a lengthy, laborious process, especially the clinical trial for the approval of a candidate.
This cannot be done in a few weeks,” said Becker.
The vaccine is a so-called vector vaccine based on the “Modified Vaccinia Virus Ankara” (MVA) as vector.
The MVA vaccine virus was already generated at the LMU more than 30 years ago as a vaccine against smallpox.
The MVA viruses are so attenuated that they can serve as harmless vectors for other vaccines.
According to the announcement, the clinical trial will be conducted by Prof.
Marylyn Addo from the University Medical Center Hamburg-Eppendorf (UKE).
“For many procedures in this development process, the experience gained in the MVA-MERS study can serve as a blueprint,” says Addo.
“Regulatory preparations for the new vaccine have also already begun for the clinical trial.
Official recruitment of test persons can only take place after a positive vote by the ethics committee, but interested parties can already register now by sending an e-mail [e-mail protected].
This vector has already been successfully used at the DZIF for the development of a vaccine against the MERS coronavirus, a close relative of SARS-CoV-2; the first clinical testing of this MERS vaccine has been completed and further clinical development is ongoing.
The basic virus has been fully characterised and, together with genetically modified variants, is now available in more than 12 countries.
We already know the side effect profile and immunogenicity of the basic vaccine very well,” said the expert.
“We thus have a platform technology and can in principle place any foreign genetic information under the control of our vaccine virus.
It is a proven vector system for which large-scale production is already established,” said Sutter.